Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ENHERTU vs AURLUMYN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Enhertu (fam-trastuzumab deruxtecan-nxki) is a HER2-directed antibody-drug conjugate (ADC). The antibody is a humanized anti-HER2 Ig G1, and the small molecule DXd is a topoisomerase I inhibitor. Upon binding to HER2 on tumor cells, the ADC undergoes internalization and intracellular cleavage, releasing DXd which causes DNA damage and apoptotic cell death.
Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.
Unresectable or metastatic HER2-positive breast cancer after prior anti-HER2-based regimen in metastatic setting,Metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer after prior chemotherapy in metastatic setting,Unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma after prior trastuzumab-based regimen,HER2-positive non-small cell lung cancer with activating HER2 mutation after prior systemic therapy,HER2-positive solid tumors (tumor agnostic) after prior systemic therapy and no satisfactory alternative
Treatment of relapsed or refractory multiple myeloma,Treatment of relapsed or refractory mantle cell lymphoma
5.4 mg/kg intravenously every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.
Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.
Terminal elimination half-life is approximately 5.5 days (range 4.5–7.5 days) for the antibody-drug conjugate, supporting every-3-week dosing.
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 30-40 hours in severe renal impairment (Cr Cl <30 m L/min).
DXd, the released payload, is primarily metabolized by CYP3A4.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C8.
Primarily biliary/fecal excretion (approximately 95% as unchanged drug); renal excretion is negligible (<1%).
Primarily renal excretion of unchanged drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
Trastuzumab deruxtecan: Approximately 99% bound to plasma proteins (primarily to albumin).
Approximately 85-90% bound to serum albumin.
Approximately 10–12 L (approx. 0.14–0.17 L/kg for a 70 kg adult), indicating distribution primarily in vascular space.
0.5 L/kg, indicating distribution primarily into extracellular fluid with limited tissue penetration.
Not applicable; administered intravenously (100% bioavailability).
Oral bioavailability is 50-60% due to first-pass metabolism and incomplete absorption.
No dose adjustment recommended for mild to moderate renal impairment (Cr Cl ≥30 m L/min). No data for severe renal impairment (Cr Cl <30 m L/min).
GFR ≥30 m L/min: no adjustment. GFR <30 m L/min: not recommended (no data).
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose to 4.4 mg/kg. Child-Pugh C: Not recommended.
Child-Pugh A: no adjustment. Child-Pugh B or C: not recommended (no data).
Safety and efficacy not established; no recommended dose.
Not established; safety and efficacy not determined in pediatric patients.
No specific dose adjustment. Monitor for toxicity, especially in patients aged ≥65 years due to limited data.
No specific dose adjustment; monitor renal function and hematologic toxicity more frequently.
WARNING: INTERSTITIAL LUNG DISEASE and EMBRYO-FETAL TOXICITY. Interstitial lung disease (ILD) and pneumonitis, including fatal cases, have occurred. Monitor for signs and symptoms of ILD and withhold, dose reduce, or permanently discontinue based on severity. Exposure during pregnancy can cause embryo-fetal harm; advise patients of these risks.
None.
Interstitial lung disease/pneumonitis,Left ventricular ejection fraction (LVEF) reduction,Neutropenia,Fever, infection, or thrombocytopenia,Embryo-fetal toxicity
Hematologic toxicity (neutropenia, thrombocytopenia, anemia), infection risk, peripheral neuropathy, cardiotoxicity (heart failure), embryo-fetal toxicity.
None listed.
Hypersensitivity to AURLUMYN or any of its components.
No specific food interactions are known; however, ENHERTU may cause nausea, vomiting, and diarrhea. Patients should avoid heavy, spicy, or fatty foods if gastrointestinal side effects occur and maintain adequate hydration.
Avoid alcohol. No specific food interactions, but maintain a balanced diet. Take with food or milk if gastrointestinal upset occurs.
Based on its mechanism of action (topoisomerase I inhibitor) and animal studies, trastuzumab deruxtecan is expected to cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, administration of trastuzumab deruxtecan to pregnant rats during organogenesis resulted in embryofetal toxicity including decreased fetal weight and increased fetal malformations at exposures below the recommended human dose based on AUC. Due to the potential for genotoxicity and inhibition of rapidly dividing cells, there is a high teratogenic risk, particularly during the first trimester. During second and third trimesters, fetal growth restriction and oligohydramnios may occur due to HER2 receptor inhibition, although the deruxtecan component primarily drives toxicity. Effective contraception should be used during treatment and for at least 7 months after the last dose.
First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and preterm birth. Avoid in pregnancy unless benefit outweighs risk.
There are no data on the presence of trastuzumab deruxtecan in human milk, its effects on the breastfed child, or milk production. Due to the potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for at least 7 months after the last dose. The M/P ratio is unknown.
No data on excretion in human milk; M/P ratio unknown. Due to potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for at least 2 weeks after last dose.
There are no specific dose adjustment guidelines for ENHERTU during pregnancy. The recommended dose is 5.4 mg/kg as an intravenous infusion every 3 weeks. Pregnancy may alter drug pharmacokinetics due to increased plasma volume, reduced albumin, changes in hepatic metabolism and renal clearance. However, no pharmacokinetic studies have been conducted in pregnant women. Therefore, the standard dosing should be used with caution, and clinical judgment should be applied based on maternal and fetal monitoring. Dose reductions or delays may be considered if significant toxicities (e.g., ILD, neutropenia, hepatic impairment) occur. Due to the high risk of fetal harm, use in pregnancy is not recommended unless the maternal benefit justifies the risk.
No specific dosing adjustments established for pregnancy. Pregnancy-induced pharmacokinetic changes (increased volume of distribution, enhanced renal clearance) may reduce drug exposure; consider therapeutic drug monitoring if available.
Monitor for interstitial lung disease (ILD) and pneumonitis; withhold ENHERTU for grade 1 ILD and permanently discontinue for grade 2 or higher. Assess left ventricular ejection fraction (LVEF) before and during treatment; withhold for any grade of reduction. Premedicate with antiemetics per institutional guidelines. Do not substitute with trastuzumab or ado-trastuzumab emtansine.
AURLUMYN is a proprietary name for auranofin, an oral gold compound used for rheumatoid arthritis. Monitor for oral ulcerations, dermatitis, and proteinuria. Renal function and CBC should be checked monthly. Avoid concurrent use with penicillamine, antimalarials, immunosuppressants, or cytotoxic drugs. Onset of action may be delayed 3-6 months.
Report new or worsening cough, shortness of breath, or fever immediately as these may be signs of lung problems.,Notify your doctor of any nausea, vomiting, diarrhea, or constipation as these can be managed with medications.,Avoid pregnancy during treatment and for 7 months after last dose; use effective contraception.,Do not breastfeed during treatment and for 1 month after last dose.,Inform your doctor of all medications you take, including over-the-counter drugs and supplements.
Take exactly as prescribed; do not adjust dose without consulting your doctor.,Report any mouth sores, skin rash, unexplained bruising, or change in urine color immediately.,Regular blood and urine tests are required to monitor for side effects.,May take 3-6 months to feel full benefit; do not stop suddenly.,Avoid alcohol as it may increase risk of liver toxicity.,Use effective contraception during treatment and for 6 months after stopping.,Do not take any other medications (including OTC) without approval from your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ENHERTU vs AURLUMYN, answered by our medical review team.
ENHERTU is a Antineoplastic Agent that works by Enhertu (fam-trastuzumab deruxtecan-nxki) is a HER2-directed antibody-drug conjugate (ADC). The antibody is a humanized anti-HER2 Ig G1, and the small molecule DXd is a topoisomerase I inhibitor. Upon binding to HER2 on tumor cells, the ADC undergoes internalization and intracellular cleavage, releasing DXd which causes DNA damage and apoptotic cell death.. AURLUMYN is a Antineoplastic Agent that works by Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ENHERTU and AURLUMYN depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ENHERTU is: 5.4 mg/kg intravenously every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.. The standard adult dose of AURLUMYN is: Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ENHERTU and AURLUMYN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ENHERTU is classified as Category C. Based on its mechanism of action (topoisomerase I inhibitor) and animal studies, trastuzumab deruxtecan is expected to cause fetal harm when administered to a pregnant woman. There. AURLUMYN is classified as Category C. First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.